U.S. Markets open in 2 hrs 19 mins

Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis

Zacks Equity Research
1 / 1

URI vs. SSD: Which Stock Should Value Investors Buy Now?

URI vs. SSD: Which Stock Is the Better Value Option?

Eli Lilly & Company LLY announced that the FDA has approved the inclusion of additional data on the label of its psoriasis injection, Taltz. With the latest approval, Taltz label will now include data for psoriasis involving the genital area, which impacts roughly 63% of psoriasis patients over the course of their disease.

Taltz is already marketed for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy as well as for active psoriatic arthritis. Taltz works by specifically targeting IL-17A, a protein that plays a role in driving underlying inflammation in psoriasis.

The drug recorded sales of $146.5 million in the first quarter of 2018. The label expansion will expand the eligible patient population of the drug, which should drive sales going forward.

The approval for genital psoriasis was based on data from a study evaluating patients with moderate-to-severe psoriasis involving the genital area. In the study, Taltz demonstrated a significant improvement compared to placebo at 12 weeks in the severity of psoriasis affecting the genital area, overall psoriasis, genital itch and the impact of genital psoriasis on sexual activity in such patients.

Though many other drugs like Novartis’ NVS Cosentyx, J&J’s JNJ Tremfya and AbbVie’s ABBV Humira are approved to treat plaque psoriasis, Lilly claims Taltz is now the first and only FDA approved treatment for genital psoriasis

Taltz is also being studied in a late-stage study for axial spondyloarthritis.

Year to date, Lilly’s shares have declined 2.6% compared with the industry’s decline of 3.8%.


Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>              

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Novartis AG (NVS) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research